RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Madrigal Pharmaceuticals Stock

Madrigal Pharmaceuticals Revenue 2024

Madrigal Pharmaceuticals Revenue

83.92 M USD

Ticker

MDGL

ISIN

US5588681057

WKN

A2APCZ

In 2024, Madrigal Pharmaceuticals's sales reached 83.92 M USD, a 0% difference from the 0 USD sales recorded in the previous year.

The Madrigal Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e3.71-
2028e2.64-
2027e1.93-
2026e1.01-
2025e0.37-
2024e0.08-
2023--
2022--
2021--
2020--
2019--
2018--
2017--
2016--
2015--
2014--
2013--
20120-
20110.01-
20100.01-
20090.14-
20080-
20070-
2006--
2005--
20040-

Madrigal Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Madrigal Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Madrigal Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Madrigal Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Madrigal Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Madrigal Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Madrigal Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Madrigal Pharmaceuticals’s growth potential.

Madrigal Pharmaceuticals Revenue, EBIT and net profit per share

DateMadrigal Pharmaceuticals RevenueMadrigal Pharmaceuticals EBITMadrigal Pharmaceuticals Net Income
2029e3.71 B undefined0 undefined2.25 B undefined
2028e2.64 B undefined1.66 B undefined1.41 B undefined
2027e1.93 B undefined1.04 B undefined823.86 M undefined
2026e1.01 B undefined104.73 M undefined55.67 M undefined
2025e371.45 M undefined-407.72 M undefined-387.33 M undefined
2024e83.92 M undefined-610.36 M undefined-608.43 M undefined
20230 undefined-380.5 M undefined-373.63 M undefined
20220 undefined-293.6 M undefined-295.4 M undefined
20210 undefined-242.5 M undefined-241.8 M undefined
20200 undefined-206.7 M undefined-202.2 M undefined
20190 undefined-95 M undefined-83.9 M undefined
20180 undefined-40.7 M undefined-32.8 M undefined
20170 undefined-32.1 M undefined-31.2 M undefined
20160 undefined-25.2 M undefined-26.4 M undefined
20150 undefined-3.2 M undefined-6.8 M undefined
20140 undefined-84 M undefined-86.2 M undefined
20130 undefined-87.6 M undefined-90.2 M undefined
2012100,000 undefined-60.9 M undefined-62.8 M undefined
20117.6 M undefined-45.4 M undefined-47.4 M undefined
201014.8 M undefined-36.9 M undefined-37.5 M undefined
2009144.2 M undefined80.5 M undefined79.1 M undefined
20082.6 M undefined-93.7 M undefined-92.6 M undefined
2007700,000 undefined-66.2 M undefined-122.1 M undefined
20060 undefined-59.2 M undefined-59.1 M undefined
20050 undefined-71.2 M undefined-68.9 M undefined
2004200,000 undefined-45.3 M undefined-45.9 M undefined

Madrigal Pharmaceuticals stock margins

The Madrigal Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Madrigal Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Madrigal Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Madrigal Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Madrigal Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Madrigal Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Madrigal Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Madrigal Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Madrigal Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Madrigal Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Madrigal Pharmaceuticals Margin History

Madrigal Pharmaceuticals Gross marginMadrigal Pharmaceuticals Profit marginMadrigal Pharmaceuticals EBIT marginMadrigal Pharmaceuticals Profit margin
2029e0 %0 %60.63 %
2028e0 %62.89 %53.33 %
2027e0 %53.8 %42.62 %
2026e0 %10.42 %5.54 %
2025e0 %-109.76 %-104.28 %
2024e0 %-727.3 %-725 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %-60,900 %-62,800 %
20110 %-597.37 %-623.68 %
20100 %-249.32 %-253.38 %
20090 %55.83 %54.85 %
20080 %-3,603.85 %-3,561.54 %
20070 %-9,457.14 %-17,442.86 %
20060 %0 %0 %
20050 %0 %0 %
20040 %-22,650 %-22,950 %

Madrigal Pharmaceuticals Aktienanalyse

What does Madrigal Pharmaceuticals do?

Madrigal Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of top-quality therapy products for various metabolic disorders. The company is headquartered in Conshohocken, Pennsylvania and was founded in 2011. The history of Madrigal Pharmaceuticals Inc began with the collaboration of Fred Middleton and Paul Friedman. Both are experienced drug developers and have already achieved some successes in the industry. They discovered the promising active ingredient resveratrol for the treatment of obesity and other metabolic disorders in mice. The idea of applying this concept to humans led to the founding of Madrigal Pharmaceuticals Inc. The business model of Madrigal Pharmaceuticals Inc consists of developing high-quality peptide and lipid-based drugs. The company specifically focuses on the treatment of metabolic disorders such as non-alcoholic fatty liver disease (NAFLD), lipid metabolism disorders, and NASH (non-alcoholic steatohepatitis). The goal is to develop innovative therapy products that bring about significant improvements in patients. Madrigal Pharmaceuticals Inc has several divisions in research and development. One of the most important specialties is the discovery of ACTOS resistance. ACTOS is a drug used to treat diabetic metabolic disorders. However, Madrigal Pharmaceuticals Inc has recognized that ACTOS does not work in some patients, and that this patient group is at higher risk of obesity, NAFLD, and NASH. Therefore, the company is developing therapeutics that target this patient group and are more effective than ACTOS. Another specialty of Madrigal Pharmaceuticals is the Myocardial Peptide Modulator (MMP). This active ingredient is a potential approach to treating metabolic disorders and heart failure. Another important division of Madrigal Pharmaceuticals Inc is the development of drugs targeting PCSK9 inhibition. PCSK9 is a protein that contributes to increased cholesterol levels. The goal is to improve understanding of the mechanism of action of PCSK9 and its various mechanisms in order to develop effective therapy products. The company has already developed several products that are in the clinical phase and are highly effective. One of the most remarkable products is MGL-3196. This product is a farnesoid X receptor agonist that has proven to be promising in the treatment of NASH and lipid metabolism disorders. Madrigal Pharmaceuticals Inc has also formed partnerships with other companies to strengthen collaboration in the research and development of products. One important partnership is with Shionogi, a Japanese pharmaceutical company. This collaboration has helped develop an innovative therapy product for the treatment of obesity that uses a targeted gene silencer. Overall, Madrigal Pharmaceuticals Inc has established itself as a company that develops innovative products for the treatment of metabolic disorders. The company strives to create the possibility for patients to receive effective therapy that is able to improve the mechanism of action of metabolic disorders. Madrigal Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Madrigal Pharmaceuticals's Sales Figures

The sales figures of Madrigal Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Madrigal Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Madrigal Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Madrigal Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Madrigal Pharmaceuticals stock

How much revenue did Madrigal Pharmaceuticals generate this year?

Madrigal Pharmaceuticals has achieved a revenue of 83.92 M USD this year.

How much was the turnover of the company Madrigal Pharmaceuticals compared to the previous year?

The revenue of Madrigal Pharmaceuticals has increased by 0% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Madrigal Pharmaceuticals?

The revenue of Madrigal Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Madrigal Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Madrigal Pharmaceuticals so important for investors?

The revenue of Madrigal Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Madrigal Pharmaceuticals pay?

Over the past 12 months, Madrigal Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Madrigal Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Madrigal Pharmaceuticals?

The current dividend yield of Madrigal Pharmaceuticals is .

When does Madrigal Pharmaceuticals pay dividends?

Madrigal Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Madrigal Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Madrigal Pharmaceuticals located?

Madrigal Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Madrigal Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Madrigal Pharmaceuticals from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did Madrigal Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/16/2024.

What was the dividend of Madrigal Pharmaceuticals in the year 2023?

In the year 2023, Madrigal Pharmaceuticals distributed 0 USD as dividends.

In which currency does Madrigal Pharmaceuticals pay out the dividend?

The dividends of Madrigal Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Madrigal Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Madrigal Pharmaceuticals

Our stock analysis for Madrigal Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Madrigal Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.